{"id":497151,"date":"2013-03-08T09:46:02","date_gmt":"2013-03-08T04:16:02","guid":{"rendered":"http:\/\/stockviz.biz\/index.php\/?p=497151"},"modified":"2013-03-10T20:02:55","modified_gmt":"2013-03-10T14:32:55","slug":"analysis-glenmark","status":"publish","type":"post","link":"https:\/\/stockviz.biz\/index.php\/2013\/03\/08\/analysis-glenmark\/","title":{"rendered":"Analysis: GLENMARK"},"content":{"rendered":"<p>Today\u2019s pick is GLENMARK [stockquote]GLENMARK[\/stockquote]. The stock has been on an uptrend since the start of the year. It saw its 52 weeks high of Rs. 552 in January, and since then has been on a pennant formation. The decreasing volume levels are suggesting that it is soon going to decide on its next move. In the last three months, the stock moved <b>+11<strong>%<\/strong><\/b> Vs. -1% of the Nifty\u2019s.<\/p>\n<p><a title=\"GLENMARK technical analysis chart\" href=\"http:\/\/stockviz.biz\/StockDive?TICKER=GLENMARK\"><img loading=\"lazy\" decoding=\"async\" style=\"margin: 10px;padding-left: 0px;padding-right: 0px;padding-top: 0px;border: 0px\" title=\"GLENMARK technical analysis chart\" alt=\"GLENMARK technical analysis chart\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/STOCK.GLENMARK2013-03-08.png\" width=\"602\" height=\"482\" border=\"0\" \/><\/a><\/p>\n<p>Oscillator <a href=\"http:\/\/stockviz.biz\/index.php\/part-ix-relative-strength-index-rsi\/\">RSI<\/a> and <a href=\"http:\/\/stockviz.biz\/index.php\/technical-trading\/chande-momentum-oscillator\/\">CMO<\/a> are in no man\u2019s land. The stock is currently trading in the middle of the <a href=\"http:\/\/stockviz.biz\/index.php\/2012\/07\/27\/bollinger-bands\/\">Bollinger band<\/a>s. Short-term technical just saw a <b>bullish dragonfly doji<\/b> and a <b>bearish<\/b> 18&#215;4 SMA cross-over.<\/p>\n<p>The <a href=\"http:\/\/stockviz.biz\/index.php\/part-xi-moving-average-convergence-divergence-macd2\/\">MACD<\/a> line is moving along the signal line since a month, not suggesting any directional move for the stock. Also, the Long-term and short-term <a href=\"http:\/\/stockviz.biz\/index.php\/technical-trading\/guppy-multiple-moving-averages\/\">GMMA<\/a> lines are contracting, unable to provide any outlook for the stock.<\/p>\n<p><a title=\"GLENMARK correlation chart\" href=\"http:\/\/stockviz.biz\/StockDive?TICKER=GLENMARK\"><img loading=\"lazy\" decoding=\"async\" style=\"margin: 10px;padding-left: 0px;padding-right: 0px;padding-top: 0px;border: 0px\" title=\"GLENMARK correlation chart\" alt=\"GLENMARK correlation chart\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/cor.GLENMARK2013-03-08.png\" width=\"630\" height=\"210\" border=\"0\" \/><\/a><\/p>\n<p>GLENMARK\u2019s average <a href=\"http:\/\/stockviz.biz\/index.php\/tag\/correlation\/\">correlation<\/a> with the <a href=\"http:\/\/stockviz.biz\/Technicals.aspx?INDEX=NIFTY\">Nifty<\/a> is <b>0.33<\/b> which is <b>positive<\/b>. The scrip will be replicating movement of Nifty. [stockquote]NIFTYBEES[\/stockquote]<\/p>\n<p><a title=\"GLENMARK volatility chart\" href=\"http:\/\/stockviz.biz\/StockDive?TICKER=GLENMARK\"><img loading=\"lazy\" decoding=\"async\" style=\"margin: 10px;padding-left: 0px;padding-right: 0px;padding-top: 0px;border: 0px\" title=\"GLENMARK volatility chart\" alt=\"GLENMARK volatility chart\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/wordpress\/2013\/03\/Vol.GLENMARK2013-03-08.png\" width=\"630\" height=\"210\" border=\"0\" \/><\/a><\/p>\n<p>GLENMARK has a historical <a href=\"http:\/\/stockviz.biz\/index.php\/2012\/07\/17\/understanding-volatility-part-i\/\">volatility<\/a> in the range of 0.4 to 0.8. The scrip\u2019s volatility is currently in the middle of the range.<\/p>\n<p>Given these technicals, we suggest a short-term<b> Hold. <\/b>A long-term call could be taken depending on the directional breakout of the pennant in formation. It is also suggested to have a tight <a href=\"http:\/\/stockviz.biz\/index.php\/2012\/10\/09\/setting-trailing-stop-loss-percentages\/\">trailing stop-losses<\/a> level to book profits in case of a sudden trend-reversal.<\/p>\n<h6 class=\"zemanta-related-title\" style=\"font-size: 1em\">Related articles<\/h6>\n<ul class=\"zemanta-article-ul zemanta-article-ul-image\" style=\"margin: 0px;padding: 0px;overflow: hidden\">\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"margin: 2px 10px 10px 2px;padding: 0px;width: 84px;text-align: left;font-size: 11px;vertical-align: top;float: left\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/www.rediff.com\/business\/report\/glenmark-initiates-studies-to-develop-new-molecule-gbr-830\/20130204.htm\" target=\"_blank\"><img decoding=\"async\" style=\"margin: 0px;padding: 0px;border: 0px currentColor;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/142874651_80_80.jpg\" \/><\/a><a style=\"padding: 5px 2px 0px;height: 80px;line-height: 12pt;overflow: hidden;text-decoration: none\" href=\"http:\/\/www.rediff.com\/business\/report\/glenmark-initiates-studies-to-develop-new-molecule-gbr-830\/20130204.htm\" target=\"_blank\">Glenmark initiates studies to develop new molecule<\/a><\/li>\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"margin: 2px 10px 10px 2px;padding: 0px;width: 84px;text-align: left;font-size: 11px;vertical-align: top;float: left\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/www.biomedreports.com\/20130130120904\/glenmark-s-consolidated-revenue-increases-by-33-96-to-rs-13812-59-million-for-q3-fy-12-13.html\" target=\"_blank\"><img decoding=\"async\" style=\"margin: 0px;padding: 0px;border: 0px currentColor;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/141655369_80_80.jpg\" \/><\/a><a style=\"padding: 5px 2px 0px;height: 80px;line-height: 12pt;overflow: hidden;text-decoration: none\" href=\"http:\/\/www.biomedreports.com\/20130130120904\/glenmark-s-consolidated-revenue-increases-by-33-96-to-rs-13812-59-million-for-q3-fy-12-13.html\" target=\"_blank\">Glenmark&#8217;s Consolidated Revenue Increases by 33.96% to Rs. 13812.59 Million for Q3 FY 12-13<\/a><\/li>\n<li class=\"zemanta-article-ul-li-image zemanta-article-ul-li\" style=\"margin: 2px 10px 10px 2px;padding: 0px;width: 84px;text-align: left;font-size: 11px;vertical-align: top;float: left\"><a style=\"padding: 2px;text-decoration: none\" href=\"http:\/\/news.in.msn.com\/business\/article.aspx?cp-documentid=252169861\" target=\"_blank\"><img decoding=\"async\" style=\"margin: 0px;padding: 0px;border: 0px currentColor;width: 80px\" alt=\"\" src=\"http:\/\/i.zemanta.com\/143743732_80_80.jpg\" \/><\/a><a style=\"padding: 5px 2px 0px;height: 80px;line-height: 12pt;overflow: hidden;text-decoration: none\" href=\"http:\/\/news.in.msn.com\/business\/article.aspx?cp-documentid=252169861\" target=\"_blank\">Glenmark launches anti-malarial drug in UK market<\/a><\/li>\n<\/ul>\n<div class=\"roundedCornerSmall\" style=\"height: 200px;padding-bottom: 0px;padding-left: 10px;width: 100%;padding-right: 0px;padding-top: 0px;border: grey 1px solid\">\n<div style=\"margin-top: 70px;float: left\"><a style=\"font-family: segoe ui;color: black;font-size: 18px;font-weight: 600\" href=\"http:\/\/stockviz.biz\/index.php\/2012\/11\/29\/the-stockviz-demat-account-2\/\">Open a StockViz Demat Account today!<\/a><\/div>\n<div style=\"float: right\"><a href=\"918026650232\"><img decoding=\"async\" style=\"border-width: 0px\" alt=\"call us qr code\" src=\"http:\/\/portalvhds29z8xdrqhczq.blob.core.windows.net\/web-static\/QR_CODE_DIRECT_CALL_634909979709728491.png\" \/><\/a><\/div>\n<\/div>\n<div class=\"zemanta-pixie\" style=\"height: 15px;margin-top: 10px\"><img decoding=\"async\" class=\"zemanta-pixie-img\" style=\"border: currentColor;float: right\" alt=\"\" src=\"http:\/\/img.zemanta.com\/pixy.gif?x-id=3833a8db-4edd-4b3c-9794-ead5b5414bd1\" \/><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Today\u2019s pick is GLENMARK [stockquote]GLENMARK[\/stockquote]. The stock has been on an uptrend since the start of the year. It saw its 52 weeks high of Rs. 552 in January, and since then has been on a pennant formation. The decreasing volume levels are suggesting that it is soon going to decide on its next move. &hellip; <\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[649,815],"class_list":["post-497151","post","type-post","status-publish","format-standard","hentry","category-your-money","tag-glenmark","tag-technical-analysis","entry"],"_links":{"self":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts\/497151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/comments?post=497151"}],"version-history":[{"count":0,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/posts\/497151\/revisions"}],"wp:attachment":[{"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/media?parent=497151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/categories?post=497151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stockviz.biz\/index.php\/wp-json\/wp\/v2\/tags?post=497151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}